Monday Aug 18
Top CROs dominate competition in trial totals, review finds
A breakdown of trials run by the top contract research organizations reveals that the big players are leaving little room for smaller firm to compete, according to a review by Outsourcing-Pharma.com of trials in clinicaltrials.gov.
New Market Report: Covance Inc. (CVD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Covance Inc. is drug development service company. The company offers a broad range of early-stage and late-stage product development services principally to the pharmaceutical and biotechnology industries.
Covance Inc. Partners With To Provide Free Health Care To Wisconsin??'s Uninsured Patients
Covance Inc. , the world's most comprehensive drug development company and a leader in nutritional analysis, partnered with the National Association of Free and Charitable Clinics for a third year to support a day-long clinic where uninsured and underinsured patients in the Madison, Wisconsin, area were given access to free medical attention.
Covance Given "Neutral" Rating at SunTrust
's stock had its "neutral" rating reaffirmed by stock analysts at SunTrust in a report issued on Thursday.
Covance finds early phase work rebound in Q2 as central labs growth continues
The season of quarterly reports is in full swing, with CRO Covance seeing its income and revenue rise in Q2 compared with the same quarter last year due to stronger-than expected early phase development and central labs work.
Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639...
Covance Inc. today reported results for its second quarter ended June 30, 2014. Net revenue was $639 million, representing 8.0% growth from the second quarter of 2013.